SCHEMBL19734247

SCHEMBL19734247

CC(C)N1CCC(C)C2(CCC2)C1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19734248 0.94 HRH3 (0.32) HRH3
SCHEMBL19766504 0.92 — —
SCHEMBL14546271 0.82 HRH3 (0.33) HRH3
SCHEMBL19727296 0.79 — —
SCHEMBL22306023 0.79 — —
SCHEMBL19727312 0.79 — —
SCHEMBL19727289 0.79 — —
SCHEMBL16984290 0.78 HRH3 (0.31) HRH3
SCHEMBL19756445 0.78 HRH3 (0.31) HRH3
SCHEMBL19734250 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362217-A1 Substituted Piperidine Compounds Epizyme, Inc. (US) 2017-12-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362217-A1 Substituted Piperidine Compounds SMYD3, SMYD2, SNRPD3 HRH3 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback